Loading
A phase 2 trial of Trastuzumab rezetecan, Adebrelimab and SHR-8068 in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT06778031 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 54 participants planned, started 2025-02-26 and due to reach its primary completion in 2028-06. Interventions recorded: SHR-A1811, SHR-1316 and SHR-8068.
Shares SHR-8068, Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.